Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.

175.20 8.97 −4.87%
Market cap
$11.7B
P/E
234×
Fwd P/E
112×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

4,455.67 188.34 128.07 181.92
P/S ratio
10.62 12.48 8.70 9.80
P/FCF ratio
134.37 215.98 119.86 126.01
P/Operating CF
156.36 358.49 234.66 234.93
P/B ratio
3.61 4.38 3.15 3.64
EV/Sales
10.42 12.27 8.48 9.56
EV/EBITDA
78.27 60.17 40.12 46.62
EV/FCF
131.85 212.32 116.82 122.90
Current Ratio
8.36 8.37 9.20 9.05
Net Debt/EBITDA
(6.62) (5.35) (5.94) (5.52)
Debt/Equity
0.26 0.26 0.26 0.26
Earnings Yield
0.02% 0.53% 0.78% 0.55%
Free Cash Flow Yield
0.74% 0.46% 0.83% 0.79%
Free Cash Flow per Share
0.76 0.31 0.41 0.47
Book value per Share
37.02 37.45 37.36 37.44
Free Cash Flow
42.71 17.59 23.35 26.70
EV/EBIT
9,247.62 164.20 100.28 116.20
Other line items

Show all line items

Columns are period end dates